-+ 0.00%
-+ 0.00%
-+ 0.00%

SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) TABLETS IN PATIENTS WITH MODERATE TO SEVERE ACNE

Reuters·02/02/2026 12:00:00

Please log in to view news